Maxim lowered the firm’s price target on cbdMD (YCBD) to $3 from $16 but keeps a Buy rating on the shares. The firm cites the company Q2 results missing its estimates on earnings and revenue along with its “significant share dilution”, the analyst tells investors in a research note. Maxim adds however that with improved marketing execution, a cleaner capital structure, and growing momentum across its diversified product portfolio, it believes that cbdMD is positioned to return to sales growth.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YCBD: